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chain altered distribution in a much higher proportion
of patients with X-linked AS [5].
It is our experience that skin biopsy, examined with
conventional, and if needed, with confocal microscopy,
is able to virtually detect (almost) all cases of X-linked
AS [5], thus allowing to avoid or to postpone more in-
vasive and/or expensive diagnostic procedure like renal
biopsy and genetic investigations, which, in addition, are
not diagnostic in all cases.
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Reply from the Author
I thank Professors Kashtan and Rizzoni and Dr. Mas-
sella for their comments. They rightly point out the value
of immunostaining of renal biopsies for the diagnosis of
X-linked and autosomal Alport syndrome and the utility
of skin immunofluorescence in diagnosis of many cases
of X-linked Alport syndrome. The use of confocal laser
scanning microscopy (CLSM) [1–3] is an elegant tech-
nique to improve the spatial resolution of a5(IV) chain
distribution in basement membranes.
Ueda et al [3], also using CLSM, have reported that
compared with a2(IV), a5(IV) expression in GBM is re-
duced in patients with TBMD. The reduction in a5(IV)
but not a3(IV) and a4(IV) is difficult to reconcile with
the genetic evidence implicating mutations of COL4A3
and COL4A4 in TBMD.
Confirmation and clarification of the results of CLSM
of EBM and GBM is eagerly awaited. Until sequenc-
ing of the relevant collagen genes or other comprehen-
sive genetic testing is routinely and readily available, im-
munofluorescence of skin biopsies is a minimally invasive
means for diagnosis of many cases of X-linked Alport syn-
drome. If quantitative comparisons of the different a(IV)
chains in GBM permit a positive diagnosis of TBMD, this
will further strengthen our diagnostic hand.
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Diagnosis of Alport syndrome
To the Editor: Professor Gregory’s recent editorial [1]
addresses the difficulties that may arise in attempts to
distinguish Alport syndrome and thin basement mem-
brane nephropathy, particularly in children. Positive di-
agnosis of the X-linked and autosomal-recessive forms of
Alport syndrome may be made by immunostaining of re-
nal biopsy specimens for alpha chains of type IV collagen
[2, 3]. X-linked Alport syndrome can also be diagnosed by
immunostaining of skin biopsy specimens for the alpha5
chain of type IV collagen [4].
There are patients who exhibit expression of type
IV collagen chains that is indistinguishable from con-
trol, despite the presence of pathogenic mutations in the
COL4A3, COL4A4, or COL4A5 gene [3, 4]. In these
cases, estimation of prognosis and genetic counseling
would be greatly aided by the availability of molecular ge-
netic diagnostic services. More than 80% of mutations in
the COL4A5 gene can be identified by direct nucleotide
sequencing [5].
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